Trial Profile
A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs Antrodia cinnamomea (Primary)
- Indications Carcinoma; Liver cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Oneness Biotech
- 25 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 25 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 29 Mar 2023 Planned primary completion date changed from 1 May 2023 to 1 Dec 2023.